[Form 4] The Oncology Institute, Inc. Warrant Insider Trading Activity

Rhea-AI Filing Summary

Brad Hively, a director of Oncology Institute, Inc. (ticker shown as TOI), reported a sale of 20,221 shares of common stock on 08/19/2025 at a price of $4.06 per share. After the reported disposition he beneficially owned 622,980 shares in a direct capacity. The Form 4 was signed by an attorney-in-fact on 08/21/2025.

Insights

Securities Analyst

TL;DR: A director reported a modest sale that reduced direct holdings to 622,980 shares; no derivatives or additional transactions disclosed.

The filing documents a straightforward open-market sale coded "S" on 08/19/2025 for 20,221 common shares at $4.06 each. There are no derivative instruments reported in Table II and no indication of a 10b5-1 plan box checked in the visible text. The transaction appears routine and discloses remaining direct ownership, useful for monitoring insider activity but not by itself a material governance event.

Corporate Governance Expert

TL;DR: Director sale disclosed; signature executed by attorney-in-fact; disclosure meets Section 16 reporting format.

The Form 4 shows required elements: reporting person, relationship (director), transaction date, transaction code (S), number of shares sold, price, and post-transaction beneficial ownership. The signature block indicates an attorney-in-fact signed on 08/21/2025. No amendments, option exercises, or indirect ownership notes are present. This is a routine insider disclosure under Section 16.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hively Brad

(Last) (First) (Middle)

C/O THE ONCOLOGY INSTITUTE OF HOPE

18000 STUDEBAKER ROAD, SUITE 800

(Street)

CERRITOS CA 90703

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Oncology Institute, Inc. [ TOI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/19/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common stock	08/19/2025		S		20,221	D	$4.06	622,980	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Mark Hueppelsheuser, Attorney-in-fact for Brad Hively	08/21/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Brad Hively report on Form 4 for TOI?

The Form 4 reports a sale of 20,221 common shares on 08/19/2025 at $4.06 per share.

How many shares did Brad Hively own after the reported transaction?

Following the sale, Brad Hively beneficially owned 622,980 shares in a direct capacity.

Was any derivative security reported by the reporting person on this Form 4?

No. Table II for derivative securities contains no reported transactions or holdings.

Who signed the Form 4 and when was it signed?

The Form 4 was signed by Mark Hueppelsheuser, attorney-in-fact for Brad Hively on 08/21/2025.

What relationship does the reporting person have to the issuer?

The form identifies Brad Hively as a Director of the issuer.